润达医疗(603108) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 was CNY 2,439,778,208.38, representing a year-on-year increase of 23.10%[4] - The net profit attributable to shareholders for Q3 2021 was CNY 118,518,484.50, showing a decrease of 4.86% compared to the same period last year[4] - For the first nine months of 2021, the company achieved an operating revenue of CNY 6,773,088,805.26, a growth of 37.53% year-on-year[6] - The net profit attributable to shareholders for the first nine months of 2021 was CNY 325,510,480.22, an increase of 38.05% year-on-year[6] - The basic earnings per share for Q3 2021 was CNY 0.20, a decrease of 4.76% compared to the same period last year[5] - Total revenue for Q3 2021 reached ¥6,773,088,805.26, a 37.5% increase from ¥4,924,879,561.78 in Q3 2020[17] - Net profit for Q3 2021 was ¥490,536,521.09, compared to ¥353,797,314.22 in Q3 2020, representing a 38.7% growth[20] - The total comprehensive income for the third quarter of 2021 was approximately CNY 490.64 million, compared to CNY 354.38 million in the same period of 2020, representing an increase of about 38.4%[21] - Basic earnings per share for the third quarter of 2021 were CNY 0.56, up from CNY 0.41 in the same quarter of 2020, reflecting a growth of 36.6%[21] Assets and Liabilities - The total assets at the end of Q3 2021 were CNY 12,111,791,044.34, reflecting a year-on-year increase of 19.02%[5] - Total assets as of Q3 2021 amounted to ¥12,111,791,044.34, an increase from ¥10,176,547,262.92 in the previous year[17] - Total liabilities reached ¥7,765,858,329.78 in Q3 2021, compared to ¥6,096,311,368.55 in Q3 2020, marking a 27.4% rise[17] - Total current assets as of September 30, 2021, are approximately ¥7.58 billion, compared to ¥6.23 billion at the end of 2020[14] - Current assets totaled approximately $6.23 billion, with accounts receivable at approximately $3.01 billion[27] - Total liabilities reached approximately $6.10 billion, reflecting a decrease of $99.68 million from the previous period[29] - Current liabilities were approximately $5.54 billion, with short-term borrowings at approximately $3.76 billion[29] Cash Flow - The company reported a net cash flow from operating activities of CNY -82,683,773.58 for the year-to-date, a decline of 158.68% year-on-year[6] - Cash inflow from operating activities for the first three quarters of 2021 was CNY 7.07 billion, compared to CNY 5.57 billion in the same period of 2020, indicating an increase of approximately 27%[24] - Cash outflow from operating activities totaled CNY 7.15 billion in the first three quarters of 2021, compared to CNY 5.43 billion in the same period of 2020, marking an increase of about 31.6%[24] - The net cash flow from operating activities for the third quarter of 2021 was negative CNY 82.68 million, a decline from a positive CNY 140.91 million in the same quarter of 2020[24] - The net cash flow from investing activities was negative CNY 327.38 million in the third quarter of 2021, compared to negative CNY 908.63 million in the same quarter of 2020, showing an improvement[25] - Cash inflow from financing activities for the third quarter of 2021 was CNY 4.96 billion, compared to CNY 4.19 billion in the same period of 2020, representing an increase of approximately 18.4%[25] - The net cash flow from financing activities was CNY 273.24 million in the third quarter of 2021, a decrease from CNY 832.89 million in the same quarter of 2020[25] - The ending cash and cash equivalents balance as of the third quarter of 2021 was CNY 518.06 million, down from CNY 605.15 million at the end of the same quarter in 2020[25] Shareholder Information - The total number of common shareholders at the end of the reporting period is 20,142[11] - The largest shareholder, Hangzhou Gongshu District State-owned Investment Holding Group Co., Ltd., holds 116,000,000 shares, representing 20.02% of total shares[11] - The second-largest shareholder, Zhu Wenyi, holds 54,938,408 shares, accounting for 9.48% of total shares[11] - The company has a total of 11,000,063 shares held by Tibet Born Asset Management Co., Ltd. - Born Tianfu No. 7 Private Securities Investment Fund, representing 1.90%[13] - The company has no pledged, marked, or frozen shares among the top ten shareholders[11] Research and Development - The company increased its market promotion efforts and R&D investments, leading to a significant rise in sales and R&D expenses compared to the previous year[6] - Research and development expenses for Q3 2021 were ¥82,109,791.21, up from ¥56,437,169.79 in Q3 2020, indicating a 45.6% increase[20] - The company plans to expand its market presence and invest in new technologies to drive future growth[19] Inventory and Receivables - Accounts receivable increased to approximately ¥3.80 billion from ¥3.01 billion year-over-year[14] - Inventory as of September 30, 2021, is approximately ¥1.47 billion, up from ¥1.15 billion at the end of 2020[14] - The company's goodwill increased to approximately ¥2.02 billion from ¥1.79 billion year-over-year[14] - The company holds inventory valued at approximately $1.15 billion[27]